Dr Reddy's launches Toripalimab to treat nasopharyngeal cancer in India

Q: How long will it take to read this news story?

The story "Dr Reddy&#039;s launches Toripalimab to treat nasopharyngeal cancer in India" has 483 words across 25 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Dr Reddy&#039;s launches Toripalimab to treat nasopharyngeal cancer in India" was covered 5 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 272 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23915374</li><li>URL: https://beamstart.com/news/dr-reddys-launches-toripalimab-to-17327814999899</li></ul>

Business Standard Logo Business Standard 5h ago

Dr Reddy's launches Toripalimab to treat nasopharyngeal cancer in India - Business Standard

Quick Summary:

However, the prognosis for patients in advanced stages is poor, and India is among the top five countries in the world in terms of disease burden.

Toripalimab is an anti-PD-1 monoclonal antibody that blocks PD-1 interactions with PD-L1 and PD-L2, thereby enhancing the immune response to target and kill tumour cells through improved receptor internalisation.

Prior to Toripalimab, chemotherapy (gemcitabine and cisplatin) was the standard treatment for RM-NPC in India.